

Patent  
Attorney Docket No. 65731-76121

**AMENDMENTS TO THE SPECIFICATION:**

Please amend paragraph 0026 of the specification as follows:

[0026] The invention provides a screening system for identifying agents that affect the degradation/transactivation of HIF-1 alpha. The screening system comprises preparing and admixing a substantially purified preparation of a polypeptide having at least an amino acid of SEQ ID NO:5 (minimum N-TAD) or the oligonucleotide sequence encoding a smaller fragment thereof (SEQ ID NO:6 (residues 547-575; Fig. 28)) or described mutants thereof with a test agent; and monitoring, by any suitable means, an inhibition of transactivation of HIF-1 alpha, whereby an inhibition of the transactivation of HIF-1 alpha identifies an HIF-1 alpha antagonist. This screening system can also be used to identify agents which activate the transactivation of HIF-1 alpha.

Please amend paragraph 0042 of the specification as follows:

[0042] Thus, ~~in a ninth aspect of~~ according to the present invention, there is provided a method of screening for a substance which mimics the activity of a PYI motif or <sup>564</sup>P spanning polypeptide (e.g. residues 547-575) or portion thereof, the method comprising the steps of contacting the test substances with a HIF-1 alpha specific binding partner, e.g. VHL or a portion thereof, and determining whether the test substances bind to the specific binding partner.